Related Experiment Video

Updated: Jul 20, 2026

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
07:50

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model

Published on: September 3, 2020

Promising though not yet proven: emerging strategies to promote myocardial salvage

David G Rizik1, Kevin J Klassen, Denise A Dowler

  • 1Scottsdale Heart Group, Scottsdale Healthcare Hospital, Scottsdale, Arizona 85258, USA. davidrizik@aol.com

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|September 14, 2006
PubMed

Insights

Despite successful acute myocardial infarction treatments, long-term results remain poor. Novel therapies are needed to protect heart muscle and improve left ventricular function for better survival outcomes.

Area of Science:

  • Cardiology
  • Cardiovascular Research

Background:

  • Advances in acute myocardial infarction (AMI) treatment achieve early vessel patency but often yield suboptimal long-term clinical outcomes.
  • Successful percutaneous coronary intervention (PCI) does not guarantee recovery of left ventricular (LV) function, a key determinant of survival.
  • Congestive heart failure and mortality persist despite technically successful PCI, highlighting unmet therapeutic needs.

Purpose of the Study:

  • To review the acute pathological mechanisms contributing to LV dysfunction post-AMI, even after successful revascularization.
  • To explore emerging mechanical and pharmacological therapies aimed at myocardial salvage and LV function preservation.
  • To discuss strategies targeting microvascular protection and restoration of myocyte metabolic function.

Main Methods:

  • Review of current literature on AMI pathophysiology and treatment outcomes.
  • Analysis of data on myocyte injury and microvascular collapse mechanisms.
  • Examination of novel therapeutic approaches for myocardial protection.

Main Results:

  • Early revascularization success does not prevent long-term LV dysfunction.
  • Myocardial injury and microvascular dysfunction significantly impact long-term prognosis.
  • Emerging therapies focus on microvascular protection to restore myocyte function.

Conclusions:

  • Current AMI treatments require enhancement to improve long-term clinical results.
  • Preserving LV function and salvaging myocardium are critical for improving survival post-AMI.
  • Microvascular protection strategies represent a promising frontier in AMI management.

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...